|
Ulcerative Colitis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
To determine potential associations of interleukin-1 receptor antagonist (IL-1ra), tumour necrosis factor alpha (TNF alpha), and tumour necrosis factor beta (TNF beta) gene polymorphisms with ulcerative colitis or subsets of ulcerative colitis in a Spanish population.
|
10321759 |
1999 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
High levels of KV1.3 in CD4 and CD8 positive T-cells infiltrates are associated with production of pro-inflammatory IL-17A and TNF-α in active UC.
|
24793818 |
2014 |
|
Ulcerative Colitis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Eight functional SNPs were associated with anti-TNF response either among patients with CD (TLR5 (rs5744174) and IFNGR2 (rs8126756)), UC (IL12B (rs3212217), IL18 (rs1946518), IFNGR1 (rs2234711), TBX21 (rs17250932) and JAK2 (rs12343867)) or in the combined cohort of patient with CD and UC (IBD) (NLRP3 (rs10754558), IL12B (rs3212217) and IFNGR1 (rs2234711)) (P<0.05).
|
28139755 |
2018 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Eligible patients were anti-TNF naïve adults with moderately to severely active UC.
|
29372480 |
2018 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
In common with peripheral chronic inflammatory diseases such a rheumatoid arthritis and ulcerative colitis, evidence now exists for the involvement of inflammatory cytokines, for example tumour necrosis factor (TNF) and interleukins (IL), in neurological disorders.
|
17347265 |
2007 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that anti-IL-6R antibody therapy may lead to aggravation of anti-TNF resistant ulcerative colitis.
|
26668517 |
2015 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Treatment of the two major forms of IBD, Crohn's disease and ulcerative colitis, involves the reduction of inflammation with toxic immunosuppressive drugs or blocking of the pro-inflammatory effects of tumour necrosis factor-alpha (TNF-alpha) with antibodies.
|
17207256 |
2007 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
To assess comparative efficacy and safety of different therapies as first-line (biologic-naïve) and second-line (prior exposure to anti-tumour necrosis factor(TNF)-α) agents for moderate-severe UC, through a systematic review and network meta-analysis, and appraise quality of evidence (QoE) using grading of recommendations, assessment, development and evaluation (GRADE) approach.
|
29205406 |
2018 |
|
Ulcerative Colitis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We investigate the association between TNF promoter polymorphisms and susceptibility to ulcerative colitis (UC) in the Chinese Han ethnic population.
|
16863613 |
2006 |
|
Ulcerative Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The expression of Caudal-related homeobox transcription factor 2 (CDX2) is impaired by tumor necrosis factor-α (TNF-α)-mediated activation of nuclear factor-κB (NF-κB) in ulcerative colitis (UC).
|
27333824 |
2017 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Multiple Cytokine Profiling: A New Model to Predict Response to Tumor Necrosis Factor Antagonists in Ulcerative Colitis Patients.
|
30544140 |
2019 |
|
Ulcerative Colitis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Tumor necrosis factor (TNF) superfamily gene-15 (SF15) polymorphisms were associated with CD (OR 2.68; 95% CI 1.86-3.86), while TNF-308 polymorphisms (OR 1.82; 95% CI 1.15-2.9), cytotoxic T lymphocyte antigen (CTLA)-4 (OR 2.75; 95% CI 1.22-6.22) and MICA allele (OR 2.41; 95% CI 1.89-3.07) were associated with ulcerative colitis in Asians.
|
21887729 |
2012 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Adalimumab is a recombinant monoclonal antibody to tumor necrosis factor alpha (TNFα) used in the treatment of inflammatory and autoimmune conditions, including ulcerative colitis (UC).
|
30648028 |
2018 |
|
Ulcerative Colitis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Combination therapy was not superior in any of the registration trials for Crohn's disease and ulcerative colitis for TNF antagonists, vedolizumab, or ustekinumab.
|
29462391 |
2018 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Rates of anti-TNF therapy during emergency admission for UC have increased whereas overall colectomy rates have fallen.
|
31714573 |
2019 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
The cumulative incidence of anti-TNF exposure varied from 20.9% to 31.4% for CD and from 8.0% to 13.5% for UC.
|
30205699 |
2018 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
The levels of LMR, endotoxin, and TNF-α were higher in the UC group than in the CD group, but 25(OH)D was lower (p<0.05).
|
30429108 |
2019 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
The risk of death was statistically significantly lower in patients treated with anti-TNF therapy for CD (21.4 vs. 30.1 per 1,000 person-years, OR 0.78, 0.65-0.93) but not for UC (23.0 vs. 30.9 per 1,000 person-years, OR 0.87, 0.63-1.22).
|
29336432 |
2018 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
The activation of A3AR by 2-Cl-IB-MECA significantly decreased TNF-α and IL-1β production and attenuated the NF-κB p65 activation in colonic tissues from patients with UC.
|
31714673 |
2020 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Baicalin significantly increased the activity of SOD, CAT and GSH-Px in colon tissue of rats with UC, but significantly decreased the content of MDA, IL-1β, MPO, PEG2 and TNF-α in colon tissue of rats with UC.
|
31103874 |
2019 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Here, we test whether IL-10 can favour the response to glucocorticoids by improving the TNFα-induced intestinal barrier damage (assessed by transepithelial electrical resistance) in Caco-2 monolayers, and their possible implications on glucocorticoid responsiveness in active ulcerative colitis.
|
26090671 |
2015 |
|
Ulcerative Colitis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Based on the results of the pivotal clinical GEMINI trials, vedolizumab was approved for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD) refractory or intolerant to either conventional therapy or TNFα inhibitors.
|
29930467 |
2018 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Aberrant activation of the immune response to resident microflora contributes to overproduction of TNF-α in the mucosal tissue of the gastrointestinal tract; a hallmark of UC.
|
30615542 |
2019 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
The cytokine TNF is thought to play a major role in the immunopathogenesis of ulcerative colitis, and anti-TNF antibodies are considered as cornerstones of clinical therapy.
|
31747580 |
2019 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor α inhibitors dramatically changed the management of moderate-to-severe phenotypes of ulcerative colitis.
|
27960557 |
2017 |